

## DAFTAR PUSTAKA

1. PERKI KKGJ dan K. Pedoman Tatalaksana Gagal Jantung. *Perhimpun Dr Spes Kardiovask Indones*. Published online 2020:848-853.
2. Kapiloff MS, Emter CA. The cardiac enigma: current conundrums in heart failure research. *F1000Research*. 2016;5.
3. Sahle BW, Owen AJ, Mutowo MP, Krum H, Reid CM. Prevalence of heart failure in Australia: a systematic review. *BMC Cardiovasc Disord*. 2016;16:1-6.
4. Hobbs FDR, Roalfe AK, Davis RC, Davies MK, Hare R. Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). *Eur Heart J*. 2007;28(9):1128-1134.
5. Wangko LC, Budiono B, Lefrandt RL. Angiografi Koroner Indikasi, Kontraindikasi, Dan Proteksi Terhadap Radiasi. *J Biomedik JBM*. 2012;4(3).
6. Kay P, Sabate M, Costa MA. *Cardiac Catheterization and Percutaneous Interventions*. CRC Press; 2004.
7. Modi K, Padala SA, Gupta M. Contrast-induced nephropathy. Published online 2017.
8. Maaniitty T, Stenström I, Uusitalo V, et al. Incidence of persistent renal dysfunction after contrast enhanced coronary CT angiography in patients with suspected coronary artery disease. *Int J Cardiovasc Imaging*. 2016;32:1567-1575.
9. Liu C, Mor MK, Palevsky PM, et al. Postangiography increases in serum creatinine and biomarkers of injury and repair. *Clin J Am Soc Nephrol*. 2020;15(9):1240-1250. doi:10.2215/CJN.15931219



S. Guidelines for contrast media from the European Society of Urogenital  
*Am J Roentgenol*. 2003;181(6):1463-1471.

Published online 2022:1-12.

12. Elserafy AS, Okasha N, Hegazy T. Prevention of contrast induced nephropathy by ischemic preconditioning in patients undergoing percutaneous coronary angiography. *Egypt Hear J.* 2018;70(2):107-111.
13. Xu T, Lin M, Shen X, et al. Association of the classification and severity of heart failure with the incidence of contrast-induced acute kidney injury. *Sci Rep.* 2021;11(1):15348.
14. Members AF, Dickstein K, Vardas PE, et al. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy Develop. *Europace.* 2010;12(11):1526-1536.
15. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J.* 2016;37(27):2129-2200m. doi:10.1093/eurheartj/ehw128
16. Kemp CD, Conte J V. The pathophysiology of heart failure. *Cardiovasc Pathol.* 2012;21(5):365-371.
17. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. *Circulation.* 2005;111(21):2837-2849.
18. Floras JS. Alterations in the sympathetic and parasympathetic nervous systems in heart failure. *Hear Fail a companion to Braunwald's Hear Dis 4th edn Elsevier, Amsterdam.* Published online 2019:181-200.
19. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure: physiology, pathophysiology, and clinical  
A, Costanzo E, Cosentino J, et al. Contrast-induced nephropathy: physiology, risk factors, and prevention. *Saudi J Kidney Dis Transplant.* *J Am Coll Cardiol.* 2009;54(19):1747-1762.



2018;29(1):1-9.

21. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2022;79(17):e263-e421.
22. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Vol 145.; 2022. doi:10.1161/CIR.0000000000001063
23. Rear R, Bell RM, Hausenloy DJ. Contrast-induced nephropathy following angiography and cardiac interventions. *Heart.* 2016;102(8):638-648.
24. Tsai TT, Patel UD, Chang TI, et al. Contemporary Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions: Insights From the NCDR Cath-PCI Registry. *JACC Cardiovasc Interv.* 2014;7(1):1-9. doi:https://doi.org/10.1016/j.jcin.2013.06.016
25. Widaningsih Y, Natsir R, Arif M, et al. Analysis of Serum Creatinine Level and Contrast Volume in Contrast Induced Nephropathy Incidence after Percutaneous Coronary Intervention. *Int J Sci Basic Appl Res.* 2017;32(3):186-193. <http://gssrr.org/index.php?journal=JournalOfBasicAndApplied>
26. Stolker JM, McCullough PA, Rao S, et al. Pre-procedural glucose levels and the risk for contrast-induced acute kidney injury in patients undergoing coronary angiography. *J Am Coll Cardiol.* 2010;55(14):1433-1440.



Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in chronic heart failure and preserved, mid-range and reduced ejection fraction: of the ESC Heart Failure Long-Term Registry. *Eur J Heart Fail.*

2017;19(12):1574-1585.

28. Chyrchel M, Hałubiec P, Łazarczyk A, et al. Low ejection fraction predisposes to contrast-induced nephropathy after the second step of staged coronary revascularization for acute myocardial infarction: a retrospective observational study. *J Clin Med*. 2020;9(6):1812.
29. He H, Chen XR, Chen YQ, Niu TS, Liao YM. Prevalence and predictors of contrast-induced nephropathy (CIN) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI): a meta-analysis. *J Interv Cardiol*. 2019;2019.
30. Silver SA, Shah PM, Chertow GM, Harel S, Wald R, Harel Z. Risk prediction models for contrast induced nephropathy: systematic review. *Bmj*. 2015;351.
31. Barzi F, Miri R, Sadeghi R, et al. A randomized double blind placebo controlled trial examining the effects of pentoxifylline on contrast induced nephropathy reduction after percutaneous coronary intervention in high risk candidates. *Iran J Pharm Res*. 2019;18(2):1040-1046. doi:10.22037/ijpr.2019.12557.10977
32. Aspelin P. Nephrotoxicity in high-risk patients study of iso-osmolar and low-osmolar non-ionic contrast media study investigators: nephrotoxic effects in high-risk patients undergoing angiography. *N Engl J Med*. 2003;348:491-499.

